A5078435189- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Lung Cancer Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Immune cells in cancer
- Acute Lymphoblastic Leukemia research
- Radiopharmaceutical Chemistry and Applications
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Ethics in Clinical Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Economic and Financial Impacts of Cancer
- Multiple and Secondary Primary Cancers
- Effects of Radiation Exposure
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
University of California, Los Angeles
2016-2025
UCLA Health
2016-2025
Dana-Farber Cancer Institute
2025
UCLA Jonsson Comprehensive Cancer Center
2021-2024
University of Minnesota
2002-2024
Ronald Reagan UCLA Medical Center
2024
UCLA Medical Center
2017-2024
APLA Health
2022
Hefei Institutes of Physical Science
2022
Chinese Academy of Sciences
2022
BackgroundAlthough EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some do respond these therapies; however, there is a lack of understanding the characteristics lung responsive blockade.Patients and methodsWe retrospectively analyzed de-identified clinical molecular data on 171 cases treated with inhibitors from Yale Cancer Center, Memorial Sloan Kettering University California Los Angeles, Dana Farber Institute. A separate cohort 383 cancer sequencing...
Abstract Mitochondria are critical to the governance of metabolism and bioenergetics in cancer cells 1 . The mitochondria form highly organized networks, which their outer inner membrane structures define bioenergetic capacity 2,3 However, vivo studies delineating relationship between structural organization mitochondrial networks activity have been limited. Here we present an functional analysis phenotypes non-small cell lung (NSCLC) using integrated platform consisting positron emission...
This first-in-human, dose-escalation and dose-expansion study evaluated the safety, tolerability, antitumor activity of datopotamab deruxtecan (Dato-DXd), a novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate in solid tumors, including advanced non-small-cell lung cancer (NSCLC).
Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to potent, exatecan-derived topoisomerase I inhibitor payload via plasma-stable, selectively cleavable linker.
PURPOSE The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NSCLC). METHODS Patients received Dato-DXd 6 mg/kg or 75 mg/m 2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) overall (OS). Objective response rate, duration response, secondary points. RESULTS In total, 299 305 randomly...
PURPOSE Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142 ) evaluated the safety and clinical activity of Dato-DXd in patients advanced/metastatic non–small cell lung cancer (NSCLC) actionable genomic alterations progressing on or after targeted therapy platinum-based chemotherapy. PATIENTS AND METHODS...
BACKGROUND Merkel cell carcinoma (MCC) is an aggressive skin cancer with a recurrence rate of >40%. Of the 2000 MCC cases per year in United States, most are caused by polyomavirus (MCPyV). Antibodies to MCPyV oncoprotein (T‐antigens) have been correlated tumor burden. The present study assesses clinical utility MCPyV‐oncoprotein antibody titers for prognostication and surveillance. METHODS detection was optimized laboratory. A cohort 219 patients newly diagnosed were followed...
We retrospectively analyzed non-small cell lung cancer (NSCLC) patients from a single center treated with pembrolizumab on the KEYNOTE-001 trial and evaluated association between treatment-related adverse events (trAEs) clinical outcomes. Investigators reported AEs graded them according to Common Terminology Criteria for Adverse Events v4.0, labeling as unlikely, possibly, or probably treatment-related. labeled possibly/probably related were considered trAEs this analysis. The relationship...
Abstract Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to potent topoisomerase I inhibitor payload via stable tetrapeptide-based cleavable linker. Preliminary results from the phase 1 TROPION-PanTumor01 study demonstrate that Dato-DXd has encouraging antitumor activity and manageable safety profile in patients with non-small cell lung cancer (NSCLC) (Meric-Bernstam, ASCO 2021) those...
Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery cytotoxic agents tumor cells. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising topoisomerase I inhibitor payload monoclonal antibody directed trophoblast cell-surface antigen 2 (TROP2), protein that broadly expressed in several types solid tumors. Dato-DXd being investigated across multiple...
663 Background: Dato-DXd is a TROP2-directed antibody-drug conjugate under investigation in various solid tumor types. We report updated results patients (pts) with locally advanced/metastatic urothelial cancer (la/m UC) from the ongoing phase 1 TROPION-PanTumor01 study (NCT03401385). Methods: Pts unresectable la/m UC (stage III/IV) treated ≥1 prior line of therapy, including an immune checkpoint inhibitor, received 6 mg/kg Q3W. Primary objectives were safety and tolerability. Secondary...
Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC), CD8 cells melanoma. We sought examine the relationship between these distinct variables blockade long-term benefit.
Abstract Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 IgG1 mAb covalently linked to highly potent topoisomerase I (Topo I) inhibitor payload via stable, tumor selective, tetrapeptide-based cleavable linker. Dato-DXd has previously shown encouraging activity in heavily pretreated patients (pts) with metastatic TNBC (Krop, SABCS 2021). Here we report updated results from the TROPION-PanTumor01 study pts...
Abstract Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors pembrolizumab in patients with advanced NSCLC. Experimental Design: We used high-dimensional mass cytometry (CyTOF) baseline blood samples NSCLC treated pembrolizumab. CyTOF data were analyzed by machine-learning algorithms (Citrus, tSNE) and...
603 Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized anti-TROP2 IgG1 monoclonal antibody covalently linked to highly potent topoisomerase I inhibitor payload via plasma-stable, tumor-selective, tetrapeptide-based cleavable linker. Dato-DXd has shown encouraging antitumor activity and manageable safety profile in patients (pts) with solid tumors. We report preliminary results pts advanced/metastatic (a/m) urothelial cancer from the ongoing...
8593 Background: Brain metastases (mets) occur frequently in pts with NSCLC, particularly certain AGAs, and indicate poor prognosis. For treatment options are limited once targeted therapy platinum-based chemotherapy (Pt-CT) become ineffective. The phase 2 TROPION-Lung05 trial (NCT04484142) of Dato-DXd has demonstrated systemic efficacy a manageable safety profile heavily pretreated a/m NSCLC AGAs who progressed following Pt-CT; here we report an exploratory analysis intracranial (IC)...